These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29360883)

  • 21. Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae.
    Tostes RO; Rodrigues TC; da Silva JB; Schanoski AS; Oliveira ML; Miyaji EN
    PLoS One; 2017; 12(1):e0170157. PubMed ID: 28103277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-silico design and evaluation of an epitope-based serotype-independent promising vaccine candidate for highly cross-reactive regions of pneumococcal surface protein A.
    Afshari E; Cohan RA; Sotoodehnejadnematalahi F; Mousavi SF
    J Transl Med; 2023 Jan; 21(1):13. PubMed ID: 36627666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA).
    Katsurahara T; Hotomi M; Yamauchi K; Billal DS; Yamanaka N
    J Infect Chemother; 2008 Dec; 14(6):393-8. PubMed ID: 19089550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel method for production and purification of untagged pneumococcal surface protein A from clade 1.
    da Costa Rodrigues T; Zorzete P; Miyaji EN; Gonçalves VM
    Appl Microbiol Biotechnol; 2024 Apr; 108(1):281. PubMed ID: 38570417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
    Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP.
    Cao J; Chen D; Xu W; Chen T; Xu S; Luo J; Zhao Q; Liu B; Wang D; Zhang X; Shan Y; Yin Y
    Vaccine; 2007 Jun; 25(27):4996-5005. PubMed ID: 17524530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Strategy To Protect against Influenza Virus-Induced Pneumococcal Disease without Interfering with Commensal Colonization.
    Greene CJ; Marks LR; Hu JC; Reddinger R; Mandell L; Roche-Hakansson H; King-Lyons ND; Connell TD; Hakansson AP
    Infect Immun; 2016 Jun; 84(6):1693-1703. PubMed ID: 27001538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.
    Yamamoto M; McDaniel LS; Kawabata K; Briles DE; Jackson RJ; McGhee JR; Kiyono H
    Infect Immun; 1997 Feb; 65(2):640-4. PubMed ID: 9009325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective properties of a fusion pneumococcal surface protein A (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice.
    Piao Z; Akeda Y; Takeuchi D; Ishii KJ; Ubukata K; Briles DE; Tomono K; Oishi K
    Vaccine; 2014 Sep; 32(43):5607-13. PubMed ID: 25132335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.
    Yamamoto M; Briles DE; Yamamoto S; Ohmura M; Kiyono H; McGhee JR
    J Immunol; 1998 Oct; 161(8):4115-21. PubMed ID: 9780183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal and systemic immunization with a novel attenuated pneumococcal vaccine candidate confer serotype independent protection against Streptococcus pneumoniae in mice.
    Wu K; Yao R; Wang H; Pang D; Liu Y; Xu H; Zhang S; Zhang X; Yin Y
    Vaccine; 2014 Jul; 32(33):4179-88. PubMed ID: 24945468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.
    Chen X; Li B; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Zhang Y; Wu Y
    Med Microbiol Immunol; 2019 Apr; 208(2):215-226. PubMed ID: 30707297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice.
    Oma K; Zhao J; Ezoe H; Akeda Y; Koyama S; Ishii KJ; Kataoka K; Oishi K
    Vaccine; 2009 May; 27(24):3181-8. PubMed ID: 19446189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades.
    Darrieux M; Moreno AT; Ferreira DM; Pimenta FC; de Andrade ALSS; Lopes APY; Leite LCC; Miyaji EN
    J Med Microbiol; 2008 Mar; 57(Pt 3):273-278. PubMed ID: 18287288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal immunization with PsaA protein, using chitosan as a delivery system, increases protection against acute otitis media and invasive infection by Streptococcus pneumoniae.
    Xu JH; Dai WJ; Chen B; Fan XY
    Scand J Immunol; 2015 Mar; 81(3):177-85. PubMed ID: 25565478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
    Miyaji EN; Dias WO; Tanizaki MM; Leite LC
    FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2.
    Wortham C; Grinberg L; Kaslow DC; Briles DE; McDaniel LS; Lees A; Flora M; Snapper CM; Mond JJ
    Infect Immun; 1998 Apr; 66(4):1513-20. PubMed ID: 9529075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model.
    Roche H; Håkansson A; Hollingshead SK; Briles DE
    Infect Immun; 2003 Mar; 71(3):1033-41. PubMed ID: 12595413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a pneumococcal conjugate vaccine based on chemical conjugation of polysaccharide serotype 6B to PspA.
    Santiesteban-Lores LE; Cabrera-Crespo J; Carvalho E
    Microb Pathog; 2021 Sep; 158():105092. PubMed ID: 34274454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.